Biological
GT719 Injection
GT719 Injection is a biological therapy with 5 clinical trials. Currently 5 active trials ongoing.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
5(100%)
Phase Distribution
Ph early_phase_1
3
60%
Ph phase_1
2
40%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
3(60.0%)
Phase 1Safety & dosage
2(40.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 13 (60.0%)
Phase 12 (40.0%)
Trials by Status
recruiting5100%
Recent Activity
5 active trials
Showing 5 of 5
recruitingearly_phase_1
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
NCT07132112
recruitingearly_phase_1
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
NCT07131254
recruitingearly_phase_1
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
NCT07122076
recruitingphase_1
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
NCT06948981
recruitingphase_1
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209
Clinical Trials (5)
Showing 5 of 5 trials
NCT07132112Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
NCT07131254Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
NCT07122076Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
NCT06948981Phase 1
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
NCT07021209Phase 1
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5